Late-Breaking Research: Immunology 3

• LB252 · PDF ABN202：一种靶向TROP2的IFN-beta突变蛋白融合蛋白，克服ADC耐药并引发持久的CD8⁺ T细胞依赖性抗肿瘤免疫 ABN202, a TROP2-targeted IFN-beta mutein fusion protein, overcomes ADC resistance and elicits durable CD8⁺ T cell-dependent antitumor immunity Hee Geon Park, Myeung Ryun Seo, Hyun Kyung Lee, Sang Moo Lee, Su Jin Ryu, Ho Jin Lee, Rae Eon Kim, Sung Hyun Hong, Su Jin Lee, Sang In Lee, Seung Hwa Jeong, Jae Mun Kim, Sung Youl Hong, Jangsoon Lee, Naoto T. Ueno, Yeon Hee Park, Young Kee Shin
• LB253 · PDF A-911的发现：一种强效、口服生物利用度良好的5-HT7拮抗剂，可促进DC1介导的T细胞交叉致敏和抗肿瘤免疫 Discovery of A-911, a potent, orally bioavailable 5-HT7 antagonist that promotes DC1-mediated T-cell cross-priming and anti-tumor immunity Kenneth D. Bromberg, Jacob Gorman, Jun Guo, Douglas E. Kline, Daniel T. Cohen, Paul Ellis, David Peetz, Luis Rodriguez, Sven Malchow, Cara Hrusch, Ryan Duggan, Min Cheng, Todd Hopkins, Bailin Shaw, Val Manaves, Danli Towne, Sujatha Gopalakrishnan
• LB254 · PDF 重定向巨细胞病毒免疫以对抗乳腺肿瘤用于免疫治疗 Redirecting cytomegalovirus immunity against breast tumors for immunotherapy Catarina Maia, Philip Salu, Rithika Medari, Remi Marrocco, Eduardo Lucero Meza, Kwangsun Yoo, Andrew Lowy, Christopher Benedict, Tatiana Hurtado de Mendoza
• LB257 · PDF MST-0312：一种靶向性LTBR激动剂，旨在诱导三级淋巴结构（TLS）和高内皮微静脉（HEV）以治疗实体瘤 MST-0312: Targeted LTBR agonist designed to induce tertiary lymphoid structures (TLS) and high endothelial venules (HEV) for the treatment of solid tumors Marta Lewandowska, Ann White, Lucy Penfold, Fevzi Demircioglu, Charly Brown, Robert de Jonge, Ray Jupp, Pascal Merchiers
• LB258 LB258 用LAG3导向的白细胞介素-2靶向肿瘤特异性T细胞可防止T细胞耗竭并重振抗肿瘤免疫 Targeting tumor-specific T cells with LAG3-directed interleukin-2 prevents T cell exhaustion and reinvigorates antitumor immunity Zhenhua Ren, Xiaohng Yu, Yang-Xin Fu
• LB259 · PDF 一种新型肿瘤微环境响应性pro-TCE疗法可最大限度减少细胞因子释放，实现更安全的实体瘤治疗 A novel tumor-microenvironment-responsive pro-TCE therapy minimizes cytokine release for safer solid tumor treatment Yang Wang, Wei Huang, Lixia Cao, Cui Feng, Lixia Gu, Fangdun Jiang, Yifan Yang, Qi Zhang, Chen Li, Ming Zhou, Cancan Li, Bonan Yan, Ziping Wei, Yuhong Zhou
• LB260 · PDF 一种新型anti-PD-1×CTLA-4×VEGF三特异性抗体实现肿瘤选择性免疫检查点阻断并具有强效抗肿瘤活性 A novel anti-PD-1×CTLA-4×VEGF tri-specific antibody enables tumor-selective immune checkpoint blockade with potent anti-tumor activity Xiaochuan Ma, Jie Zhao, Gang Deng, Guoyong Bian, Xinping Huang, Shu Wang, Zhibin Xu, Zhendong Xue, Limin Zhang, Chunyue Wang, Hanxiao Ying, Emily Wu, Jun Feng, Min Hu, Feng He
• LB261 · PDF ProTCE-PSMA：一种用于前列腺癌的新型治疗性PSMA/CD3前药 ProTCE-PSMA, a novel therapeutic PSMA/CD3 prodrug for prostate cancer Pu Pu, Le Huang, Xiaoning Li, Ting Zhang, Huaixin Dang, Xiaoying Yang, Qiuchen Zheng, Weiyun Wen, Zhendong Xue, Yuchang Mao, Limin Zhang, Chunyue Wang, Hanxiao Ying, Emily Wu, Jun Feng, Min Hu, Feng He
• LB263 · PDF BCG047：一种靶向FOLR1的新型重链抗体偶联药物，展现出卓越的临床前抗肿瘤疗效 BCG047, a novel heavy chain antibody-drug conjugate targeting FOLR1, demonstrates outstanding preclinical antitumor efficacy Benny Yang, Yifu Zhang, Yangyang Xu, Chengzhang Shang
• LB264 · PDF 化冷为热：靶向TNF增强双特异性T细胞衔接器在实体瘤中的活性 Turning cold tumors hot: Targeted TNF potentiates the activity of bispecific T cell engagers in solid tumors Gudrun Thorhallsdottir, Ramon Benz, Pinuccia Faviana, Francesco Bartoli, Samuele Cazzamalli, Emanuele Puca, Dario Neri, Abdullah Elsayed
• LB265 · PDF AGB101：一种同类首创的Vbeta17 x DLL3双特异性抗体，选择性重定向Vbeta17记忆T细胞以驱动强效的DLL3依赖性抗肿瘤活性 AGB101, a first-in-class Vbeta17 x DLL3 bispecific antibody, selectively redirects Vbeta17 T memory cells to drive robust DLL3 dependent anti-tumor activity Natasa Obermajer, Jessie Richardson, Daniel Masylar, Karin Thacker, Matthew V. Lorenzi, Iqbal S. Grewal
• LB266 · PDF VBC229：一种新型DLL3靶向双互补位T细胞衔接器-拓扑异构酶I抑制剂融合分子，用于实现小细胞肺癌的应答深度和持续时间 VBC229: A novel DLL3-targeting biparatopic T-cell engager-topoisomerase I inhibitor fusion molecule for depth and duration of response in small-cell lung cancer Wei (Vivian) Wang, Xuekun Zhang, Kevin Yin, Man Xu, Jim Li, Jian Tang, Xingguang Lin, Yingchun Wang, Yanwei Wang, Xin Li, Delong Zhang, Jing Li
• LB267 · PDF CYT X300：一种新型EGFR x 泛gamma delta T细胞衔接器，用于治疗实体瘤 CYT X300, a novel EGFR x pan-gamma delta T cell engager for the treatment of solid tumors James Legg, Mark Uden, Robert Good, Julie Hoong, Alex Laskowska, Fevzi Demircioglu, Roseanna Hare, Shauna Corcoran, Valentina Cazzetta, Joanna Mikulak, Luke Cave, Carlotta Cattolico, Leia Griffin, Domenico Mavilio, Natalie Mount
• LB268 · PDF 3H-10000的临床前开发：一种用于治疗FGFR2b表达癌症的新型vedotin抗体偶联药物 Preclinical development of 3H-10000, a novel vedotin antibody-drug conjugate for treatment of FGFR2b-expressing cancers Mingming Gao, Susan Liuchen, Jufang Lin, Bingshuang Xu, Yan Ding, Qiaoxin Zeng, Zhixiong Zhang, Li Cao, Chunzhe Guo, Tao Liu, Ning Jiao, Yong Peng, Shaojing Hu
• LB269 · PDF 对CDR609药理学的机制洞察支持其作为靶向免疫治疗的高潜力 Mechanistic insights into the pharmacology of CDR609 support high potential as a targeted immunotherapy Athanasia Dasargyri, Alessio Vantellini, André Fonseca, Anna Howald, Blaz Pavlovic, Alice Langer, Martina Priola, Nora Wettstein, Zoi Barou, Cedric Kiss, Hannes Merten, Sophie Barsin, Stephanie Jungmichel, Leonardo Borras
• LB270 · PDF TCE-A：一种"或门"CD19×CD20×CD3三特异性T细胞衔接器，用于B细胞恶性肿瘤和自身免疫性疾病 TCE-A: An “OR-gate” CD19×CD20×CD3 trispecific T-cell engager for B-cell malignancies and autoimmune diseases Hanxiao Ying, Emily Wu, Sizhu Duan, Dongmei Bai, Jing Wang, Pu Pu, Limin Zhang, Chunyue Wang, Min Hu, Feng He
• LB272 · PDF 新抗原 mRNA 疫苗在肝内胆管癌小鼠模型中产生抗肿瘤免疫 A neoantigen mRNA vaccine generates antitumor immunity in a murine model of intrahepatic cholangiocarcinoma Mantang Qiu, Jiacheng Lu, Xinghan Wu, Yang Liu, Guoming Shi

在会议检索中浏览本分会场